Most patients with heart valve disease may be candidates for the transcatheter aortic valve replacement (TAVR) procedure as an alternative to open-heart surgery. In August 2019, the Food and Drug Administration (FDA) expanded the eligibility criteria to patients who are at low risk for major complications associated with open-heart surgery. Previously the FDA approved TAVR devices only for patients evaluated as medium or high risk.
Since the UA Sarver Heart Center’s Structural Heart Disease team started offering the TAVR procedure in 2012, about 417 patients have benefited from this advance that requires a small incision in the groin to implant a new valve via catheter. Most patients return home the following day and recover more quickly than patients who undergo open-heart surgery.
“The technology for transcatheter valve replacement continues to advance, allowing more and more valves to be replaced less invasively,” said Kapil Lotun, MD, director of the Structural Heart Disease Program at UA Sarver Heart Center.
For more information or to refer a patient, contact:
Phone: (520) 694-8578 • Fax: (520) 694-1007 • BUMCTStructuralHeart@bannerhealth.com